Literature DB >> 27620137

In vitro residual activity of phenylalanine hydroxylase variants and correlation with metabolic phenotypes in PKU.

Roberta Trunzo1, Rosa Santacroce2, Nan Shen3, Sabine Jung-Klawitter3, Angelica Leccese2, Giuseppe De Girolamo2, Maurizio Margaglione2, Nenad Blau3.   

Abstract

Hyperphenylalaninemias (HPAs) are genetic diseases predominantly caused by a wide range of variants in the phenylalanine hydroxylase (PAH) gene. In vitro expression analysis of PAH variants offers the opportunity to elucidate the molecular mechanisms involved in HPAs and to clarify whether a disease-associated variant is genuinely pathogenic, while investigating the severity of a metabolic phenotype, and determining how a variant exerts its deleterious effects on the PAH enzyme. To study the effects of gene variants on PAH activity, we investigated eight variants: c.611A>G (p.Y204C), c.635T>C (p.L212P), c.746T>C (p.L249P), c.745C>T (p.L249F), c.809G>A (p.R270K), c.782G>C (p.R261P), c.587C>A (p.S196Y) and c.1139C>T (p.T380M), associated with different phenotypic groups. Transient expression of mutant full-length cDNAs in COS-7 cells yielded PAH proteins with PAH activity levels between 7% and 51% compared to the wild-type enzyme. With one exception (p.Y204C, which had no significant impact on PAH function), lower PAH activity was associated with a more severe phenotype (e.g. p.L249P with 7% PAH activity, 100% of classic PKU and no BH4 responsiveness), while higher activity correlated with milder phenotypes (e.g. p.T380M with 28% PAH activity, 97% of mild HPA and 83% of BH4 responsiveness). The results of the in vitro residual PAH activity have major implications, both for our understanding of genotype-phenotype correlations, and thereby existing inconsistencies, but also for the elucidation of the molecular basis of tetrahydrobiopterin (BH4) responsiveness.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  In vitro expression; Phenylalanine hydroxylase; Phenylketonuria; Tetrahydrobiopterin

Mesh:

Substances:

Year:  2016        PMID: 27620137     DOI: 10.1016/j.gene.2016.09.015

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  4 in total

1.  Unique aspects of sequence variant interpretation for inborn errors of metabolism (IEM): The ClinGen IEM Working Group and the Phenylalanine Hydroxylase Gene.

Authors:  Diane B Zastrow; Heather Baudet; Wei Shen; Amanda Thomas; Yue Si; Meredith A Weaver; Angela M Lager; Jixia Liu; Rachel Mangels; Selina S Dwight; Matt W Wright; Steven F Dobrowolski; Karen Eilbeck; Gregory M Enns; Annette Feigenbaum; Uta Lichter-Konecki; Elaine Lyon; Marzia Pasquali; Michael Watson; Nenad Blau; Robert D Steiner; William J Craigen; Rong Mao
Journal:  Hum Mutat       Date:  2018-11       Impact factor: 4.878

2.  Genotype-phenotype correlations and BH4 estimated responsiveness in patients with phenylketonuria from Rio de Janeiro, Southeast Brazil.

Authors:  Eduardo Vieira Neto; Francisco Laranjeira; Dulce Quelhas; Isaura Ribeiro; Alexandre Seabra; Nicole Mineiro; Lilian M Carvalho; Lúcia Lacerda; Márcia G Ribeiro
Journal:  Mol Genet Genomic Med       Date:  2019-03-03       Impact factor: 2.183

3.  Deubiquitinase USP19 extends the residual enzymatic activity of phenylalanine hydroxylase variants.

Authors:  Neha Sarodaya; Apoorvi Tyagi; Hyun-Jin Kim; Ju-Seop Kang; Vijai Singh; Seok-Ho Hong; Woo Jin Kim; Kye-Seong Kim; Suresh Ramakrishna
Journal:  Sci Rep       Date:  2022-08-20       Impact factor: 4.996

4.  Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels.

Authors:  Dona M Kanavy; Shannon M McNulty; Meera K Jairath; Sarah E Brnich; Chris Bizon; Bradford C Powell; Jonathan S Berg
Journal:  Genome Med       Date:  2019-11-29       Impact factor: 11.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.